At a median follow-up of 13.2 years, dose-escalated hypofractionated intensity-modulated radiation therapy led to fewer treatment failures in men with localized, intermediate-risk prostate cancer than ...

MADISON, Wis., May 7, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the European Society for Radiotherapy and Oncology (ESTRO) meeting reinforces ...

RENO, Nev. (KOLO) - Dr. Randall Gates from Gates Brain Health stopped by Morning Break to discuss prostate MRI and how this may help individuals. Prostate cancer affects 1 out of 8 men, but is much ...

SAN FRANCISCO -- For patients with recurrent prostate cancer, those with a certain subtype had clinically meaningful benefits when apalutamide (Erleada) was added to salvage radiotherapy after radical ...

(RTTNews) - Astellas Pharma Inc. (ALPMY) and Pfizer Inc. (PFE) announced longer-term follow-up results from an open-label extension of the Phase 3 ARCHES study, reporting a five-year follow up of ...